11.4 C
London
Wednesday, October 15, 2025
HomeFinTechPharmAust: Continues testing COVID-19 treatment

PharmAust: Continues testing COVID-19 treatment

Related stories

Lunar Achieves Milestone as First Scandinavian Provider to Obtain MiCA Crypto License

Revolutionizing the Crypto Landscape in Scandinavia: Lunar's Groundbreaking License...

Monzo Integrates Built-in Tax Filing Tool for Enhanced Customer Experience

Simplifying Tax Season: How Monzo's New Feature Aims to...

Former Klarna UK Chief Alex Marsh Named CEO of Salad Group

Fintech veteran Alex Marsh takes the helm at Salad...

Visa Launches Trusted Agent Protocol for AI Commerce

Innovative Security Framework Enhances Trust in AI-Driven TransactionsHighlights: Visa...

FCA’s Strategic Initiatives for Tokenisation of Investment Funds

A Comprehensive Overview of the UK Financial Conduct Authority's...
  • PharmAust (PAA) has revealed preliminary results show its drugs are effective in inhibiting COVID-19 in human lung cells
  • Researchers in Melbourne have been testing the effect monepantel (MPL) and monepantel sulfone (MPLS) has on the deadly virus
  • This recent testing found MPL and MPLS inhibited COVID-19 in human lung cells by up to 95 per cent
  • PharmAust said following these initial results, further testing will now undertaken to better understand the drug’s effect
  • PharmAust’s Chief Scientific Officer, Richard Mollard, also said the was very pleased with these latest results
  • Shares in PAA are trading 4.26 per cent in the green at 24.5 cents each

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

spot_img